Rebus Holdings, Inc., together with its subsidiaries, focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. Rebus Holdings, Inc. was incorporated in 2003 and is based in Westlake Village, California.
Rebus reported revenue of $0 for fiscal year 2022, and net income of -$1.02 million.
Figures from company filings; latest fiscal year ended December 31, 2022.
No profile data available.